OtiTopic

OtiTopic is a late-stage clinical pharmaceutical company with a mission to provide a faster treatment option for patients suspected of myocardial infarction (MI). OtiTopic has transformed the administration route of aspirin and is submitting a confidentiality agreement for commercialization and marketing in the United States. OtiTopic has developed a dry powder inhaler of aspirin for patients suspected of acute myocardial infarction, which can enter the bloodstream within two minutes. By utilizing the respiratory system as a rapid drug delivery pathway, ASPRIHALE® will revolutionize platelet inhibition and PD effects in patients with acute myocardial infarction, becoming the first non-invasive cardiac-specific treatment after FDA approval.